Thrombotic thrombocytopenic purpura in a patient with interferon treated hepatitis C successfully treated with Rituximab

  • Nishant Poddar Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, United States.
  • Jen C. Wang | jcwang5@aol.com Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, United States.

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a life threatening condition associated with formation of platelet thrombi. Deficiency of ADAM TS 13 with presence of inhibitory anti-ADAM TS 13 Immunoglobulin G antibody is seen in patients with acquired TTP. TTP in patients on interferon therapy for chronic hepatitis C has rarely been reported. Furthermore, successful treatment of an initial episode of acute refractory acquired TTP, in a patient of chronic hepatitis C during interferon therapy with Rituximab, has not been previously reported. Here we describe a case of acute refractory acquired TTP associated with pegylated interferon therapy for her chronic hepatitis C infection. Initially refractory to plasmapheresis and steroids, she was successfully treated with Rituximab and plasmaphersis without any evidence of reactivation of hepatitis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2013-01-25
Info
Issue
Section
Case Reports
Keywords:
thrombotic thrombocytopenic purpura, interferon, hepatitis C, Rituximab
Statistics
  • Abstract views: 2630

  • PDF: 206
  • HTML: 115
How to Cite
Poddar, N., & Wang, J. C. (2013). Thrombotic thrombocytopenic purpura in a patient with interferon treated hepatitis C successfully treated with Rituximab. Hematology Reports, 5(1), e2. https://doi.org/10.4081/hr.2013.e2